Use of PET and the radioligand [carbonyl-11C]WAY-100635 in psychotropic drug development

Nuclear Medicine and Biology

Volumn 27, Issue 5, 2000, Pages 515-521

  Andrée, Bengt ^a   Halldin, Christer ^a   Thorberg, Seth Olov ^b   Sandell, Johan ^a   Farde, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

5 HT(1A) receptors; Carbonyl 11C WAY 100635; Antidepressive drugs; Drug development; NAD 299; Pindolol; Positron emission tomography (PET); Robalzotan

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BUSPIRONE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PINDOLOL; ROBALZOTAN;

ANXIETY; ARTICLE; BLOOD LEVEL; BRAIN BLOOD FLOW; CONTROLLED STUDY; DEPRESSION; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG RECEPTOR BINDING; FRONTAL CORTEX; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; NEUROPSYCHIATRY; NONHUMAN; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; TEMPORAL CORTEX;

ANIMALS; BENZOPYRANS; CARBON RADIOISOTOPES; HUMANS; MACACA FASCICULARIS; PINDOLOL; PIPERAZINES; PSYCHOTROPIC DRUGS; PYRIDINES; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN ANTAGONISTS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033835334     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(00)00121-9     Document Type: Article

References (47)

1. Ahlenius S., Henriksson I., Magnusson O., Salmi P. In vivo intrinsic efficacy of the 5-HT1A receptor antagonists NAD-299, WAY-100,635 and (S)-(-)-UH-301 at rat brain monoamine receptors. Eur. Neuropsychopharmacol. 9:1999;15-19.
2. Andree B., Thorberg S.O., Halldin C., Farde L. Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology. 144:1999;303-305.
3. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors [letter]. Arch. General Psychiatry. 51:1994;248-251.
4. Assie M.B., Cosi C., Koek W. 5-HT1A receptor agonist properties of the antipsychotic, nemonapride Comparison with bromerguride and clozapine . Eur. J. Pharmacol. 334:1997;141-147.
5. Baldwin D., Rudge S. The role of serotonin in depression and anxiety. Intern. Clin. Psychopharmacol. 9:1995;41-45.
6. Berendsen H.H. Interactions between 5-hydroxytryptamine receptor subtypes Is a disturbed receptor balance contributing to the symptomatology of depression in humans? Pharmacol. & Therapeut. 66:1995;17-37.
7. Berman R.M., Darnell A.M., Miller H.L., Anand A., Charney D.S. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression A double-blind, placebo-controlled trial . Am. J. Psychiatry. 154:1997;37-43.
8. Blier P., Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol. 15:1995;217-222.
9. Chmielowiec D., Schuster D., Gengo F. Determination of pindolol in human serum by HPLC. J. Chromatograph. Sci. 29:1991;37-39.
10. Farde L. (1995) PET in neuropsychiatric drug development. In: PET for Drug Development and Evaluation (Edited by Comar D.), pp. 51-92. Kluwer Academic Publishers, Dordrecht.
11. Farde L. The advantage of using positron emission tomography in drug research. Trends Neurosci. 19:1996;211-214.
12. Farde L., Andrée B., Ginovart N., Halldin C., Thorberg S.-O. PET- determination of robalzotan (NAD-299) induced 5-HT1A receptor occupancy in the monkey brain. Neuropsychopharmacology. 22:2000;422-429.
13. 2-dopamine receptors studied by PET - A comparison to the equilibrium analysis. J. Cereb. Blood Flow Metab. 9:1989;696-708.
14. Farde L., Ginovart N., Ito H., Lundkvist C., Pike V.W., McCarron J.A., Halldin C. PET-characterization of [carbonyl-11C]WAY-100635 binding to 5-HT1A receptors in the primate brain. Psychopharmacology. 133:1997;196-202.
15. Farde L., Ito H., Swahn C.G., Pike V.W., Halldin C. Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. J. Nucl. Med. 39:1998;1965-1971.
16. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry. 49:1992;538-544.
17. Fornal C.A., Martin F.J., Metzler C.W., Jacobs B.L. Pindolol suppresses serotonergic neuronal activity and does not block the inhibition of serotonergic neurons produced by 8-hydroxy-2-(di-n-propylamino)tetralin in awake cats. J. Pharmacol. Exp. Ther. 291:1999;229-238.
18. Hall H., Halldin C., Sandell J., Werner T., Thorberg O., Sedvall G. Autoradiographic studies of the labelling of 5-HT1A receptors in the post-mortem human brain using [11C]NAD-299 and [3H]NAD-299. Eur. Neuropsychopharmacol. 8:1998;S170.
19. Hall H., Lundkvist C., Halldin C., Farde L., Pike V.W., McCarron J.A., Fletcher A., Cliffe I.A., Barf T., Wikstrom H., Sedvall G. Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635. Brain Research. 745:1997;96-108.
20. Halldin C., Swahn C., Farde L. and Sedvall G. (1995) Radioligand disposition and metabolism - Key information in early drug development. In: PET for Drug Development and Evaluation (Edited by Comar D.), pp. 55-65. Klüwer Academic Publishers, Dordrecht.
21. Hjorth S. In vivo rat brain microdialysis studies of the new 5-HT1A receptor antagonist robalzotan. Eur. Neuropsychopharmacol. 8:1998;S175.
22. Hjorth S., Carlsson A. Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors? Eur. J. Pharmacol. 129:1986;131-138.
23. Hjorth S., Sharp T. Effect of the 5-HT1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. Life Sciences. 48:1991;1779-1786.
24. Ito H., Halldin C., Farde L. Localization of 5-HT1A receptors in the living human brain using [carbonyl-11C]WAY-100635 PET with anatomic standardization technique . J. Nucl. Med. 40:1999;102-109.
25. Johansson L., Sohn D., Thorberg S.O., Jackson D.M., Kelder D., Larsson L.G., Renyi L., Ross S.B., Wallsten C., Eriksson H., Hu P.S., Jerning E., Mohell N., Westlind-Danielsson A. The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299. J. Pharmacol. Exp. Ther. 283:1997;216-225.
26. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. Neuroimage. 4:1996;153-158.
27. Larsson L.G., Stenfors C., Ross S.B. Differential regional antagonism of 8-OH-DPAT-induced decrease in serotonin synthesis by two 5-HT1A receptor antagonists. Eur. J. Pharmacol. 346:1998;209-215.
28. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 21:1999;106s-115s.
29. Millan M.J., Hjorth S., Samanin R., Schreiber R., Jaffard R., De Ladonchamps B., Veiga S., Goument B., Peglion J.L., Spedding M., Brocco M. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties . J. Pharmacol. Exp. Ther. 282:1997;148-161.
30. Millan M.J., Schreiber R., Dekeyne A., Rivet J.M., Bervoets K., Mavridis M., Sebban C., Maurel-Remy S., Newman-Tancredi A., Spedding M., Muller O., Lavielle G., Brocco M. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties II. Functional profile in comparison to clozapine and haloperidol . J. Pharmacol. Exp. Ther. 286:1998;1356-1373.
31. Moreno F.A., Gelenberg A.J., Bachar K., Delgado P.L. Pindolol augmentation of treatment-resistant depressed patients. J. Clin. Psychiatry. 58:1997;437-439.
32. Moser P.C., Sanger D.J. 5-HT1A receptor antagonists neither potentiate nor inhibit the effects of fluoxetine and befloxatone in the forced swim test in rats. Eur. J. Pharmacol. 372:1999;127-134.
33. Newman-Tancredi A., Gavaudan S., Conte C., Chaput C., Touzard M., Verriele L., Audinot V., Millan M.J. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors A [35S]GTPgammaS binding study . Eur. J. Pharmacol. 355:1998;245-2456.
34. Olivier B., Soudijn W., van Wijngaarden I. The 5-HT1A receptor and its ligands Structure and function . Prog. Drug Res. 52:1999;103-165.
35. Osman S., Lundkvist C., Pike V.W., Halldin C., McCarron J.A., Swahn C.G., Farde L., Ginovart N., Luthra S.K., Gunn R.N., Bench C.J., Sargent P.A., Grasby P.M. Characterisation of the appearance of radioactive metabolites in monkey and human plasma from the 5-HT1A receptor radioligand, [carbonyl-11C]WAY-100635 - Explanation of high signal contrast in PET and an aid to biomathematical modelling. Nucl. Med. Biol. 25:1998;215-223.
36. Pazos A., Probst A., Palacios J.M. Serotonin receptors in the human brain - III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience. 21:1987;97-122.
37. Perez V., Gilaberte I., Faries D., Alvarez E., Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 349:1997;1594-1597.
38. Perez V., Soler J., Puigdemont D., Alvarez E., Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch. Gen. Psychiatry. 56:1999;375-379.
39. Pike V.W., Halldin C., McCarron J.A., Lundkvist C., Hirani E., Olsson H., Hume S.P., Karlsson P., Osman S., Swahn C.G., Hall H., Wikstrom H., Mensonidas M., Poole K.G., Farde L. [carbonyl-11C]Desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT1A receptors in vitro and in vivo. Eur. J. Nucl. Med. 25:1998;338-346.
40. Pike V.W., McCarron J.A., Lammertsma A.A., Osman S., Hume S.P., Sargent P.A., Bench C.J., Cliffe I.A., Fletcher A., Grasby P.M. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. Eur. J. Pharmacol. 301:1996;R5-R7.
41. Raurich A., Mengod G., Artigas F., Cortes R. Displacement of the binding of 5-HT(1A) receptor ligands to pre- and postsynaptic receptors by (-)pindolol. A comparative study in rodent, primate and human brain. Synapse. 34:1999;68-76.
42. Romero L., Bel N., Casanovas J.M., Artigas F. Two actions are better than one Avoiding self-inhibition of serotonergic neurones enhances the effects of serotonin uptake inhibitors . Int. Clin. Psychopharmacol. 11:1996;1-8.
43. Sandell J., Halldin C., Chou Y.-W., C.-G. S., Thorberg S.-O., Sohn D., Werner T. and Farde L. (1999) Metabolite studies measured by HPLC in monkey plasma of the new 5-HT1A radioligand [C-11]NAD-299. J. Labelled Compd. Radiopharm. 42 (Suppl 1), 675-677.
44. Sandell J., Halldin C., Hall H., Thorberg S.-O., Werner T., Sohn D., Sedvall G., Farde L. Radiosynthesis and autoradiographic evaluation of [11C]NAD-299, a radioligand for visualization of the 5-HT1A receptor. Nucl. Med. Biol. 26:1999;159-164.
45. Tome M.B., Isaac M.T. One year real world prospective follow-up study of a major depressive episode of patients treated with paroxetine and pindolol or paroxetine for 6 weeks. International Clinical Psychopharmacology. 13:1998;169-174.
46. Wienhard K., Dahlbom M., Eriksson L., Michel C., Bruckbauer T., Pietrzyk U., Heiss W. The ECAT EXACT HR Performance of a new high resolution positron scanner . J. Comp. Ass. Tomography. 18:1994;110-118.
47. Zanardi R., Artigas F., Franchini L., Sforzini L., Gasperini M., Smeraldi E., Perez J. How long should pindolol be associated with paroxetine to improve the antidepressant response? J. Clin. Psychopharmacol. 17:1997;446-450.